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14 Abstract
15 Systemic steroid is used to treat various transplant-related complications after 
16 allogenic hematopoietic stem cell transplantation (allo-HSCT). However, 
17 measures to evaluate its impact on infections are still limited. Hence, we 
18 examined the cumulative steroid dose used within 30 days after transplant as a 
19 predictor of future risk of infections. This study included 226 patients who 
20 underwent their first allo-HSCT at Kyoto University Hospital between 2005 and 
21 2015. Sixty-one patients received transplantation from related donors, 106 
22 received unrelated BMT and 59 received unrelated single-unit CBT. Patients 
23 were categorized into 3 groups according to the cumulative steroid dose in terms 
24 of prednisolone: no-steroid group (n=174), low-dose group (<=7mg/kg) (n=22) 
25 and high-dose group (>7mg/kg) (n=30). In a multivariate analysis, high-dose 
26 steroid administration was associated with CMV antigenemia (HR 1.91, 
27 P=0.037) and bacteremia (HR 2.59, P=0.053). No impact was found on the 
28 occurrence of invasive fungal infection. In conclusion, high-dose cumulative 
29 steroid could predict high risks of bacteremia and CMV antigenemia. Additional 
30 anti-bacterial agents for fever and regular measurement of CMV antigen are 
31 recommended for whom with systemic steroid administration even after 
32 neutrophil engraftment. 
33
34 Text word count; abstract word count, 182; tables, 3; figures, 3; supplemental tables, 0
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1 Introduction
2 Systemic steroid is frequently used as a primary treatment for transplant-related 
3 complications such as graft-versus-host disease (GVHD) and non-infectious 
4 pulmonary complications after allogeneic hematopoietic stem cell 
5 transplantation (HSCT)1–3. The use of systemic steroid along with the 
6 occurrence of GVHD has been suggested to be a risk factor for various 
7 infectious diseases4–8, which are main causes of transplant-related mortality. 
8 Since the number of HSCTs with a higher risk of complications, such as cord 
9 blood transplantations (CBT) and HLA mismatch transplantations in older 
10 patients, has been increasing9–12, it is important to evaluate the effect of steroid 
11 use on clinical outcomes.
12  
13 The associations between the cumulative dose of steroid and the occurrence of 
14 side effects have been discussed in patients with non-hematologic diseases who 
15 receive systemic steroid for a prolonged period. The impact of the cumulative 
16 dose of steroid on infectious complications has been controversial, although a 
17 positive association was noted in patients taking immunosuppressive agents 
18 after solid organ transplantations13–16. Similarly, in recipients of HSCT, steroid 
19 administration could increase the risk of infectious complications because of the 
20 concomitant use of calcineurin inhibitors and the delay of immune reconstitution 
21 after HSCT. However, there is little information available regarding the steroid 
22 dose. Hence, in the present study, we examined the impact of the cumulative 
23 steroid dose on the risk of infectious diseases after HSCT in a single transplant 
24 center. 


































































3 A total of 238 patients who underwent their first allogeneic HSCT for hematologic 
4 diseases at Kyoto University Hospital from 2005 to 2015 and survived at least 30 
5 days after transplantation were included. Patients who had already started to 
6 receive steroid before transplantation were excluded. Patients who had active 
7 bacterial, fungal, or viral infection at transplantation or who had had history of 
8 invasive fungal infection before transplantation were also excluded. The 
9 Institutional Review Board of Kyoto University Hospital, where this study was 
10 organized, approved this study. 
11
12 Treatment Policy and Definition
13 Definitions
14 Neutrophil engraftment was diagnosed when an absolute neutrophil count over 
15 500/µL was observed for 3 days in a row. Acute GVHD was diagnosed and 
16 classified by each physician according to traditional criteria17. 
17  
18 Invasive fungal infections
19 βD-glucan was examined once a week, and imaging inspection and blood 
20 culture were examined for fever or other suspicious conditions. Diagnoses of 
21 invasive fungal infections were categorized into 3 types; possible, probable, and 
22 proven, based on the practice guidelines from the Infectious Diseases Society of 
23 America (IDSA) and Japanese guidelines18–20. 
24 In our hospital, antifungal prophylaxis was administered in all patients who 
25 underwent allo-HSCT. The antifungal agents that were generally used as 
26 prophylaxis were oral fluconazole, voriconazole, micafungin and liposomal 






























































Watanabe, et al.    Impact of cumulative steroid on infections after allo-SCT
4
1 amphotericin B injection, according to each patient’s history of fungal infection. 
2 All patients were hospitalized in a cleanroom of ISO Class 5 (ISO 14644-1)21 
3 before and in the early period after day0 and moved to a cleanroom of ISO Class 
4 6 (ISO 14644-1)21 after they achieved neutrophil engraftment.
5
6 CMV antigenemia and CMV disease
7 CMVpp65 antigen examinations were performed using C10/1122 method or 
8 C7-HRP23 method once a week for every patient after transplantation and 
9 examined additionally for suspicious symptoms of CMV diseases. 
10 In cases with more than 3 positive cells in 2 slides (C10/C11 method) or more 
11 than 2 positive cells out of 50000 WBC (C7-HRP method), pre-emptive therapy 
12 was given followed by close CMV-antigen monitoring22,23. Diagnosis of CMV 
13 end-organ diseases were diagnosed according to published definitions24.
14
15 Other viremias
16 Patients were examined by viral PCR detection at the timing of fever of unknown 
17 origin or any other symptoms of infection based on the judgment of each 
18 physician in charge. Viruses examined in PCR included adenovirus, BK virus, 
19 JC virus, varicella zoster virus, human herpes simplex, EB virus and other 
20 viruses according to each patient’s symptoms.
21
22 Bacteremia
23 Two sets of blood culture were examined for each patient with fever or any other 
24 symptoms suggesting infectious diseases. As our policy, antibacterial 
25 prophylaxis was not applied in every patient, except for those who were at high 
26 risk of bacterial infection, such as those with a history of repeated severe 
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1 bacterial infection or a long history of chemotherapeutic treatment.
2
3 Endpoints
4 The endpoint of this study was the incidence of various infectious diseases 
5 including invasive fungal infection, cytomegalovirus (CMV) antigenemia, and 
6 bacteremia diagnosed from 30 days to 6 months after HSCT. The cumulative 
7 steroid dose was calculated as the total amount administered per patient within 
8 30 days after transplantation, since the first steroid administration mainly began 
9 within this period as a treatment for pre-engraftment or engraftment syndrome 
10 and for acute GVHD.
11
12 Statistical analysis
13 Descriptive statistics were used to summarize variables related to patient 
14 characteristics. We calculated the cumulative steroid dose within 30 days after 
15 HSCT. The landmark day was set at 30 days after transplantation. 
16 Prednisolone-equivalent conversion was performed in accordance to the general 
17 formula25. Episodes of infectious diseases (invasive fungal infection, CMV 
18 antigenemia or disease, and bacteremia) were calculated based on cumulative 
19 incidence curves. A competing event was death without infectious disease. 
20 Cumulative incidences in the groups were compared using the Gray test. Fine 
21 and Gray’s proportional hazards model was used to evaluate the effect of 
22 cumulative steroid dose on the occurrence of infectious diseases26. The 
23 following covariates were considered; recipient’s sex, age (<50 or ≥50 years 
24 old), disease diagnosis (myeloid malignancies, lymphoid malignancies, or 
25 others), year of transplantation (2005-2009 or 2010-2016), disease status 
26 (complete remission [CR] or non-CR), donor type (bone marrow transplantation 
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1 from unrelated donor, peripheral blood stem cell transplantation from related 
2 donor, or CBT), conditioning regimen (reduced-intensity or myeloablative), 
3 GVHD prophylaxis (tacrolimus or cyclosporine in addition to mycophenolate 
4 mofetil or methotrexate), presence or absence of neutrophil engraftment at day 
5 30, and prophylactic administration of levofloxacin. All factors, in addition to the 
6 main effect, were selected with a variable retention criterion of P<0.05 in the 
7 univariate analysis and analyzed in the multivariate analysis. 
8 Although acute GVHD has been suggested to be a risk factor for infectious 
9 diseases after HSCT, we did not include acute GVHD because there was a 
10 correlation between acute GVHD and steroid administration (data not shown), 
11 and it would be inappropriate to include both in the same model. 
12 All statistical analyses were performed with Stata version 14 (Stata Corp, 
13 College Station, TX) and EZR (Saitama Medical Center, Jichi Medical University, 
14 Saitama, Japan), which is a graphical user interface for R (The R Foundation for 
15 Statistical Computing, version 3.1.1, Vienna, Austria).


































































3 Sixty-one patients received transplantation from a related donor, 106 received 
4 unrelated bone marrow grafts, and 59 received unrelated cord blood units. Their 
5 median age was 51 years (range, 17–66). Neutrophil engraftment was achieved 
6 in 203 patients (90%) by day 30 and mean neutrophil engraftment day from 
7 transplantation in each graft were 21 in bone marrow transplantation, 17 in 
8 peripheral blood stem cell transplantation and 25 in cord blood transplantation.
9 Patients were categorized into 3 groups according to the cumulative steroid 
10 dose within 30 days: no steroid group (n = 174), low-dose cumulative steroid 
11 group (7mg/kg or less of prednisolone-equivalent dose, n = 22), and high-dose 
12 cumulative steroid group (over 7mg/kg of prednisolone-equivalent dose, n =30). 
13 The cutoff value of 7mg/kg of prednisolone-equivalent dose approximately 
14 stands for initial steroid treatment against acute GVHD in Japan (1mg/kg during 
15 7 days at maximum). The reason for steroid administration was treatment for 
16 GVHD in 33 patients, engraftment syndrome in 9, and other reasons including 
17 lung complications in 10. Grade II to IV acute GVHD was diagnosed in 96 
18 patients in total. There was no obvious difference in background among the 
19 different donor sources. (Table 1).
20
21 Invasive fungal infection
22 We observed 13 cases of invasive fungal infection, including one proven case 
23 with candida bloodstream infection and 2 probable and 10 possible cases of 
24 pneumonia. The cumulative incidence of invasive fungal infection at 6 months 
25 was 5.7%, 4.5%, and 6.7% in the no-administration, low-dose, and high-dose 
26 groups, respectively (P = 0.231, Gray test) (Figure 1). Multivariate analysis 
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1 showed no association between steroid administration and the occurrence of 
2 invasive fungal infection. We found no other significant risk factor. 
3
4 CMV antigenemia and diseases
5 Eighty-six HSCT were performed from CMV-antibody (Ab) positive donors to 
6 CMV-Ab positive recipients, 10 were from CMV-Ab positive donors to CMV 
7 negative recipients and the other 103 were from CMV-Ab negative donors 
8 (Table 1).
9 A total of 105 (46%) patients were diagnosed as CMV antigenemia and 81 
10 (78%) received Ganciclovir as a pre-emptive antiviral therapy. Seven patients 
11 were pathologically diagnosed as CMV disease including colitis and hepatitis, all 
12 of whom were positive for CMV antigenemia. There were 4 cases of CMV 
13 antigenemia with clinically suspected CMV diseases, although they were not 
14 definitely diagnosed due to a lack of pathological evidence. No patient died of 
15 CMV-related complications. The cumulative incidences of CMV antigenemia at 6 
16 months in the no-administration, low-dose, and high-dose groups were 49.7%, 
17 68.8%, and 69.6%, respectively (P = 0.038) (Figure 2). Reason for steroid 
18 initiation had little impact on the occurrence of CMV antigenemia (GVHD vs 
19 other reasons: HR 2.119, P=0.089). Multivariate analysis showed that both a 
20 low-dose and high-dose of cumulative steroid administration were associated 
21 with CMV reactivation, although the association in the low-dose group was not 
22 statistically significant (low-dose vs. no-administration group: HR 1.64, P=0.100, 
23 high-dose vs. no-administration group: HR 1.91 P = 0.037). Other risk factors 
24 detected were cord blood unit as a donor source (cord blood unit vs. sibling 
25 donor: HR 1.62, P = 0.018) and recipient age over 50 years at transplantation 
26 (age >=50 vs. <50: HR 1.62, P = 0.007) (Table 2).
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1
2 Viral infections other than CMV
3 A total of 15 cases were diagnosed as viremia including Adenovirus in 1 patient, 
4 BK virus in 2, Epstein Barr virus in 1, Varicella Zoster virus in 3, and human 
5 herpes virus 6 in 7. Ten patients were in the no-administration group and there 
6 was no association between viremia and the cumulative steroid dose. 
7
8 Bacteremia
9 The cumulative incidences of bacteremia at 6 months in the no-administration, 
10 low-dose, and high-dose groups were 9.3%,15.8%, and 21.7%, respectively (P = 
11 0.224) (Figure 3). Detected microbes at the first onset of bacteremia were 
12 gram-negative rods in 15 cases, gram-positive cocci in 7 cases, and 
13 gram-positive rods in 1 case. Reason for steroid initiation had little impact on the 
14 occurrence of bacteremia (GVHD vs other reasons: HR 4.89, P=0.14). 
15 Administration of levofloxacin showed no apparent prophylactic effect on 
16 bacteremia (HR 0.73, P=0.574).
17 Multivariate analysis showed that the high-dose group was marginally 
18 associated with an increased risk of bacteremia (low-dose vs. no-administration 
19 group: HR 2.13, P =0.240, high-dose vs. no-administration group: HR 2.59, P = 
20 0.053). Regarding the microbes detected, there was no significant difference 
21 among the three groups. The other major risk factor for bacteremia was a 
22 recipient age over 50 years at transplantation, which had a HR of 2.69 (age >=50 
23 vs. <50: P = 0.021) (Table 3).
24
25 Other bacterial infections
26 The other infectious events proven as bacterial complications were 4 cases 
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1 Clostridium difficile colitis, 2 cases of pneumonia (1 of Pseudomonas 
2 aeruginosa, 1 of Stenotrophomonas maltophilia), 1 cellulitis of 
3 Coagulase-negative staphylococcus, and 1 endophthalmitis of 
4 Coagulase-negative staphylococcus.
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1 Discussion
2 In the present study, we examined the impact of the cumulative dose of steroid 
3 on infectious complications after HSCT and found associations between steroid 
4 dose and both CMV and bacterial infections following HSCT. 
5
6 Although acute GVHD and systemic steroid have been reported to be risk 
7 factors for invasive fungal infection after HSCT27–30, the cumulative steroid dose 
8 was not associated with fungal infection in our study. All patients in our hospital 
9 continued prophylactic treatment with antifungal drugs according to the risk of 
10 fungal infection, following Japanese and European guidelines31. Only 13 of 226 
11 patients had invasive fungal infection over 10 years, although our cohort 
12 included a relatively large number of cord blood transplantations. This suggests 
13 that fungal infection could be avoided regardless of the occurrence of acute 
14 GVHD, steroid use, and donor source by appropriate clinical practice.
15
16 With regard to CMV-related complications, steroid use was strongly associated 
17 with CMV antigenemia regardless of the cumulative dose, which is similar to 
18 previous reports4,32,33. Almost all the patients in our cohort were seropositive 
19 before transplant and thus CMV antigen levels must be measured regularly after 
20 HSCT. Another risk factor for CMV antigenemia was cord blood unit as a donor 
21 source, although the HR was lower than previously reported and there were no 
22 CMV-related deaths. Older patients also had a higher risk of CMV antigenemia. 
23 Contrary to a previous report4, myeloablative conditioning was not found to be a 
24 risk factor for CMV antigenemia, which is probably due to the difference in the 
25 conditioning regimen or the medication used for GVHD prophylaxis.
26
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1 High-dose, but not low-dose, cumulative steroid administration was a risk factor 
2 for bacterial infection. Anti-bacterial prophylaxis and preemptive therapies for 
3 fever of undetected origin might be better considered for patients after HSCT 
4 receiving a high cumulative dose of steroid, regardless of their neutrophil count. 
5 An advanced age at transplant was another risk factor for bacterial infection after 
6 HSCT, which was consistent with previous reports34.
7
8 The present study has several limitations. First, this is a retrospective study of 
9 small population with heterogeneous background in a single transplant center. 
10 Second, the loads of viruses other than CMV were not regularly measured and 
11 the timing of the examination was determined by each physician in charge. 
12 Finally, information on blood sugar levels was not collected, although blood 
13 sugar levels were checked regularly and treated by continuous intravenous 
14 insulin infusion, which minimized the effect of hyperglycemia on bacterial 
15 infections.
16
17 In conclusion, our study confirmed that the cumulative steroid dose could be a 
18 good prognostic marker for CMV antigenemia and bacterial infection after 
19 HSCT. These post-transplant complications must be detected and managed in 
20 the early period, particularly in elderly patients who are receiving a high 
21 cumulative dose of steroid. 
22
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1 Figure legends
2 Figure 1 Cumulative incidence of invasive fungal infection
3 Figure 2 Cumulative incidence of CMV antigenemia
4 Figure 3 Cumulative incidence of bacteremia
5






























































Table1 Patient characteristics 　 　 　 　 　 　 　
 Group by cumulative steroid dose within 30 days
No administration 
(n=174)
Low (<=7mg/kg PSL)  
(n=22)
High (>7mg/kg PSL) 
(n=30)
Total value value value
Variance
　 n*1 n %*2 n % n % P-Value
Age*3 median(range) 　 51 (17-66) 　 47 (21-66) 　 48 (20-66) 　 0.651 
　 　 　 　 　 　 　 　 　　
Male 126 103 59.2 9 40.9 14 46.7 
Gender
Female 100 71 40.8 13 59.1 16 53.3 
0.144 
　 　 　 　 　 　 　 　 　 　
Sibling 61 47 27.0 7 31.8 7 23.3 
Unrelated BM 106 81 46.6 9 40.9 16 53.3 Donor source
Unrelated CB 59 46 26.4 6 27.3 7 23.3 
0.930 
　 　 　 　 　 　 　 　 　 　
AML/MDS 134 113 64.9 11 50.0 10 33.3 
ALL/other leukemias 50 30 17.2 8 36.4 12 40.0 
Malignant lymphoma 35 25 14.4 3 13.6 7 23.3 
Disease
Aplastic anemia 7 6 3.4 0 0.0 1 3.3 
0.015 
　 　 　 　 　 　 　 　 　 　
CR 94 72 41.4 11 50.0 11 36.7 
Disease status
non CR 132 102 58.6 11 50.0 19 63.3 
0.652 
　 　 　 　 　 　 　 　 　 　
Myeloablative 112 86 49.4 11 50.0 15 50.0 
Conditioning intensity
Reduced intensity 114 88 50.6 11 50.0 15 50.0 
1.000 
　 　 　 　 　 　 　 　 　 　
No 20 18 10.5 1 4.5 1 3.4 0.477 Neutrophil 
engraftment at Day30 Yes 203 154 89.5 21 95.5 28 96.6 　
　 　 　 　 　 　 　 　 　 　






























































NO 181 142 84.0 14 63.6 25 89.3 0.079 levofloxacin 
prophylaxis Yes 38 27 16.0 8 36.4 3 10.7 
CI 19 12 6.9 2 9.1 5 16.7 
CI+MMF 35 27 15.5 4 18.2 4 13.3 
CI+MTX 137 107 61.5 13 59.1 17 56.7 
GVHD prophylaxis
CI+MMF+MTX 35 28 16.1 3 13.6 4 13.3 
0.755 
I 38 30 34.5 6 30.0 2 7.4 
II 76 47 54.0 11 55.0 18 66.7 
III 14 6 6.9 2 10.0 6 22.2 
GVHD grade  at 
onset
IV 6 4 4.6 1 5.0 1 3.7 
0.092 
CMV resopositivity Donor+/ Recipient+ 86 63 41.2 9 45.0 14 53.8 
Donor+/ Recipient- 10 9 5.9 0 0.0 1 3.8 
Donor-/ Recipient+ 85 64 41.8 10 50.0 11 42.3 
Donor-/ Recipient- 18 17 11.1 1 5.0 0 0.0 
0.527 
Acute GVHD 32 13 59.1 19 63.3 
Engraftment syndrome 9 3 13.6 6 20.0 Reason for steroid
Others 11 6 27.3 5 16.7 
*1n indicates the number of patients with each characteristics
*2% indicates the percentage of patients in each steroid group
*3Age indicates patients' age at transplantation
Calcinerin inhibitors include Tacrolimus and Cyclosporin
Abbreviation: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CR, complete remission; BM, bone 
marrow; CB, cord blood; GVHD, graft-versus-host disease; CI, Calcinerin inhibitor; MMF, mycophenolate mofetil; MTX, methotrexate; PSL, prednisolone





























































Table 2 Univariate and multivariate analysis of CMV antigenemia
Univariate analysis Multivariate analysis
Variables
HR 95% CI P-Value HR 95% CI P-Value
<50 1.00 reference 1.00 reference
Age*1






Female 0.88 (0.60-1.28) 0.499 
2005-2009 1.00 reference
Year of trasnplant
2010-2015 1.19 (0.81-1.74) 0.373 
Sibling 1.00 reference 1.00 reference
Unrelated BM 1.10 (0.68-1.78) 0.687 
Donor source





ALL/other leukemias 1.43 (0.88-2.31) 0.140 
Malignant lymphoma 0.93 (0.50-1.75) 0.824 
Disease
Aplastic anemia 1.46 (0.54-3.93) 0.453 
CR 1.00 reference
Disease status
non CR 1.18 (0.80-1.75) 0.394 































































Reduced intensity 1.19 (0.81-1.74) 0.369 
CI 1.00 reference
CI+MMF 1.00 (0.50-1.99) 0.994 
CI+MTX 0.65 (0.35-1.21) 0.178 
GVHD prophylaxis
CI+MMF+MTX 1.10 (0.54-2.22) 0.792 
NO 1.00 Neutrophil 
engraftment at day30 Yes 1.46 (0-86-2.50) 0.164 
No administration 1.00 reference 1.00 reference









*1Age indicates patients' age at transplantation
*2Low-dose indicates group who undertook low cumulative dose of steroid (<=7mg/kg of prednisolone)
*3High-dose indicates group who undertook high cumulative dose of steroid (>7mg/kg of prednisolone)
Calcinerin inhibitors include Tacrolimus and Cyclosporin
Abbreviation: HR, hazard ratio; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute
lymphoblastic leukemia; CR, complete remission; BM, bone marow; CB, cord blood; GVHD, graft-versus-host disease;
CI, Calcinerin inhibitor; MMF, mycophenolate mofetil; MTX, methotrexate; PSL, prednisolone





























































Table 3 Univariate and multivariate analysis of bacteremia
Univariate analysis Multivariate analysis
Variables
HR 95% CI P-Value HR 95% CI P-Value
<50 1.00 reference 1.00 reference
Age*1
≧50 2.40 (1.07-5.38) 0.034 2.69  (1.16-6.22) 0.021 
Male 1.00 reference
Gender
Female 1.20 (0.52-2.78) 0.671 
2005-2009 1.00 reference
Year of trasnplant
2010-2015 1.11 (0.48-2.53) 0.813 
Sibling 1.00 reference
Unrelated BM 1.28 (0.46-3.55) 0.633 Donor source
Unrelated CB 1.18 (0.37-3.72) 0.778 
AML/MDS 1.00 reference
ALL/other leukemias 1.06 (0.36-2.77) 0.917 





non CR 1.63 (0.66-3.98) 0.287 
Myeloablative 1.00 reference
Conditioning regimen
Reduced intensity 1.70 (0.72-4.03) 0.226 






























































CI+MMF 1.61 (0.31-9.13) 0.568 
CI+MTX 0.72 (0.15-3.37) 0.674 
GVHD prophylaxis
CI+MMF+MTX 1.16 (0.24-6.58) 0.864 
NO 1.00 Neutrophil 
engraftment at day30 Yes 3.86 (0.23-64.05) 0.346 
NO 1.00 Levofloxacin 
prophylaxis Yes 0.73 (0.250-2.159) 0.574 
No administration 1.00 reference 1.00 reference
Low-dose*2 1.74 (0.50-6.07) 0.390 2.13  (0.60-7.51) 0.240 steroid group
High-dose*3 2.27 (0.87-5.93) 0.097 2.59  (0.99-6.78) 0.053 
*1Age indicates patients' age at transplantation
*2Low-dose indicates group who undertook low cumulative dose of steroid (<=7mg/kg of
prednisolone)
*3High-dose indicates group who undertook high cumulative dose of steroid (>7mg/kg of
prednisolone)
Calcinerin inhibitors include Tacrolimus and Cyclosporin
Abbreviation: HR, hazard ratio; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic
leukemia; CR, complete remission; BM, bone marow; CB, cord blood; GVHD, graft-versus-host disease; CI, Calcinerin inhibitor;
MMF, mycophenolate mofetil; MTX, methotrexate; PSL, prednisolone





























































































































338x190mm (96 x 96 DPI) 
































































338x190mm (96 x 96 DPI) 
































































338x190mm (96 x 96 DPI) 
Page 30 of 29Transplant Infectious Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
